Open AccessS801 Health Insurance Coverage Limitations of Anti-Integrin Therapy in Ulcerative Colitis and Their Impact on Anti-Tumor Necrosis Factor (Anti-TNF) Therapy Utilization
Author(s) -
E Levine John
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776736.64948.9d
Subject(s) - medicine , infliximab , vedolizumab , ulcerative colitis , adalimumab , biosimilar , family medicine , inflammatory bowel disease , guideline , tumor necrosis factor alpha , gastroenterology , disease , pathology